<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40690163</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>20</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2198-6576</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>5</Issue><PubDate><Year>2025</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Rheumatology and therapy</Title><ISOAbbreviation>Rheumatol Ther</ISOAbbreviation></Journal><ArticleTitle>Guselkumab Efficacy in Biologic-Na&#xef;ve Participants with Psoriatic Arthritis and Severe Disease Activity: Post Hoc Analysis of a Phase&#xa0;3 Study.</ArticleTitle><Pagination><StartPage>925</StartPage><EndPage>940</EndPage><MedlinePgn>925-940</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40744-025-00777-3</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">The aim of this study was to evaluate guselkumab efficacy through week&#xa0;100 in participants with psoriatic arthritis (PsA) and severe disease activity or patient global assessment (PtGA).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This post hoc analysis utilized DISCOVER-2 (NCT03158285) data from 739&#xa0;biologic-na&#xef;ve adults with active PsA (&#x2265;&#x2009;5 swollen/tender joints, C-reactive protein &#x2009;&#x2265;&#x2009;0.6&#xa0;mg/dL) randomized to guselkumab every 4&#xa0;weeks (Q4W) or at weeks&#xa0;0 and 4, then every 8&#xa0;weeks (Q8W); or placebo with crossover to guselkumab Q4W at week&#xa0;24. Severe disease activity was defined as clinical Disease Activity Index for Psoriatic&#xa0;Arthritis (cDAPSA)&#x2009;&gt;&#x2009;27, Psoriatic&#xa0;Arthritis Disease Activity Score (PASDAS)&#x2009;&#x2265;&#x2009;5.4, and PtGA Arthritis&#x2009;+&#x2009;Psoriasis&#x2009;&#x2265;&#x2009;80&#xa0;mm. Least squares mean (LSM) changes in cDAPSA, PASDAS, and PtGA were estimated with mixed models for repeated measures adjusted for baseline factors.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Baseline characteristics among 648 (88%), 639 (86%), and 218 (29%) participants meeting the cDAPSA, PASDAS, and PtGA criteria for severe disease activity, respectively, were generally balanced across cohorts. LSM improvements from baseline with guselkumab Q4W/Q8W vs. placebo were -5.9 (p&#x2009;=&#x2009;0.3905)/-7.2 (p&#x2009;=&#x2009;0.0379) for cDAPSA at week&#xa0;2; -1.5/-1.5 for PASDAS&#xa0;(both p &lt; 0.0001); and -30.0/-32.1 for PtGA at week&#xa0;8 (both p&#x2009;&lt;&#x2009;0.01). Differences vs. placebo increased through week&#xa0;24 in the respective cohorts with guselkumab Q4W/Q8W: -9.8/-9.0, -1.1/-1.1, -24.0/-20.2 (all p&#x2009;&lt;&#x2009;0.0001). Through week&#xa0;100 of guselkumab Q4W/Q8W treatment, LSM improvements of 69/74%, 52/54%, and 64/63% from baseline in cDAPSA (-35.9/-35.6), PASDAS (-3.6/-3.7), and PtGA (-56.8, -55.5), respectively, were observed. Regardless of severe disease activity definition, approximately 80% of guselkumab-randomized participants who achieved low disease activity at week&#xa0;24 maintained this response at week&#xa0;100.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In biologic-na&#xef;ve participants with PsA and severe disease activity, guselkumab demonstrated early and durable clinically meaningful improvements in key PsA domains through 2&#xa0;years.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">ClinicalTrials.gov, NCT03158285.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ritchlin</LastName><ForeName>Christopher T</ForeName><Initials>CT</Initials><Identifier Source="ORCID">0000-0002-2602-1219</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Allergy/Immunology and Rheumatology, University of Rochester Medical Center, 400 Red Creek Dr, Ste 240, Rochester, NY, 14623, USA. christopher_ritchlin@URMC.Rochester.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lubrano</LastName><ForeName>Ennio</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-6189-5328</Identifier><AffiliationInfo><Affiliation>Vincenzo Tiberio Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chimenti</LastName><ForeName>Maria Sole</ForeName><Initials>MS</Initials><Identifier Source="ORCID">0000-0002-1343-1729</Identifier><AffiliationInfo><Affiliation>Rheumatology, Allergology and Clinical Immunology, Department of System Medicine, University of Rome Tor Vergata, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leibowitz</LastName><ForeName>Evan</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-0041-6984</Identifier><AffiliationInfo><Affiliation>Immunology, Johnson &amp; Johnson, Horsham, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharaf</LastName><ForeName>Mohamed</ForeName><Initials>M</Initials><Identifier Source="ORCID">0009-0003-9847-2996</Identifier><AffiliationInfo><Affiliation>Immunology, Johnson &amp; Johnson, Dubai, United Arab Emirates.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rampakakis</LastName><ForeName>Emmanouil</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, McGill University, Montreal, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>JSS Medical Research, Inc, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nantel</LastName><ForeName>Francois</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-7970-3328</Identifier><AffiliationInfo><Affiliation>Nantel Medsci Consult, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lavie</LastName><ForeName>Frederic</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-5213-257X</Identifier><AffiliationInfo><Affiliation>Johnson &amp; Johnson, Issy Les Moulineaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deodhar</LastName><ForeName>Atul</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-2130-1246</Identifier><AffiliationInfo><Affiliation>Division of Arthritis and Rheumatic Diseases, Oregon Health &amp; Science University, Portland, OR, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03158285</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Rheumatol Ther</MedlineTA><NlmUniqueID>101674543</NlmUniqueID><ISSNLinking>2198-6576</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biologic-na&#xef;ve</Keyword><Keyword MajorTopicYN="N">Composite measure</Keyword><Keyword MajorTopicYN="N">Guselkumab</Keyword><Keyword MajorTopicYN="N">Patient-reported outcome</Keyword><Keyword MajorTopicYN="N">Psoriatic arthritis</Keyword><Keyword MajorTopicYN="N">Severe disease activity</Keyword></KeywordList><CoiStatement>Declarations. Conflict of Interest: Christopher T. Ritchlin: grant/research support: AbbVie, Amgen, and UCB; consultant: AbbVie, Amgen, Eli Lilly, Gilead, Johnson &amp; Johnson, Novartis, Pfizer, and UCB. Ennio Lubrano: honoraria: AbbVie, Amgen, Eli Lilly, GlaxoSmithKline, Johnson &amp; Johnson, Novartis, and UCB. Ennio Lubrano is an Editorial Board member of Rheumatology and Therapy. Ennio Lubrano was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Maria Sole Chimenti: speaker honoraria/research grants: Eli Lilly, AbbVie, UCB, Novartis, and Johnson &amp; Johnson. Evan Leibowitz: employee: Johnson &amp; Johnson; shareholder: Johnson &amp; Johnson. Mohamed Sharaf: employee: Johnson &amp; Johnson; shareholder: Johnson &amp; Johnson. Emmanouil Rampakakis: employee: JSS Medical Research Inc.; consultant: Johnson &amp; Johnson. Francois Nantel: consultant: Johnson &amp; Johnson; shareholder: Johnson &amp; Johnson. Frederic Lavie: employee: was an employee of Johnson &amp; Johnson at the time this work was performed and currently an employee of Les Entreprises du M&#xe9;dicament, Paris, France; shareholder: Johnson &amp; Johnson. Atul Deodhar: consultant: Bristol Myers Squibb, Eli Lilly, Johnson &amp; Johnson, Novartis, Pfizer, and UCB; research grants: Eli Lilly, Novartis, Pfizer, and UCB; speaker fees: Eli Lilly, Johnson &amp; Johnson, Novartis, Pfizer, and UCB. Ethical Approval: The DISCOVER-2 (NCT03158285) study was conducted in accordance with the principles of the Declaration of Helsinki and International Council for Harmonization Guidelines for Good Clinical Practice. Each participating site&#x2019;s governing ethical body approved study protocols, and all participants provided written informed consent.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>21</Day><Hour>12</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>21</Day><Hour>12</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>21</Day><Hour>11</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40690163</ArticleId><ArticleId IdType="doi">10.1007/s40744-025-00777-3</ArticleId><ArticleId IdType="pii">10.1007/s40744-025-00777-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18:465&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">35761070</ArticleId><ArticleId IdType="pmc">9244095</ArticleId><ArticleId IdType="doi">10.1038/s41584-022-00798-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Haugeberg G, Michelsen B, Kavanaugh A. Impact of skin, musculoskeletal and psychosocial aspects on quality of life in psoriatic arthritis patients: A cross-sectional study of outpatient clinic patients in the biologic treatment era. RMD Open. 2020;6:e001223.</Citation><ArticleIdList><ArticleId IdType="pubmed">32409518</ArticleId><ArticleId IdType="pmc">7299507</ArticleId><ArticleId IdType="doi">10.1136/rmdopen-2020-001223</ArticleId></ArticleIdList></Reference><Reference><Citation>Husted JA, Thavaneswaran A, Chandran V, et al. Incremental effects of comorbidity on quality of life in patients with psoriatic arthritis. J Rheumatol. 2013;40:1349&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">23772076</ArticleId><ArticleId IdType="doi">10.3899/jrheum.121500</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerschbaumer A, Baker D, Smolen JS, et al. The effects of structural damage on functional disability in psoriatic arthritis. Ann Rheum Dis. 2017;76:2038&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">28835465</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2017-211433</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao SS, Miller N, Harrison N, et al. Systematic review of mental health comorbidities in psoriatic arthritis. Clin Rheumatol. 2020;39:217&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">31486931</ArticleId><ArticleId IdType="doi">10.1007/s10067-019-04734-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Michelsen B, Kristianslund EK, Sexton J, et al. Do depression and anxiety reduce the likelihood of remission in rheumatoid arthritis and psoriatic arthritis? Data from the prospective multicentre NOR-DMARD study. Ann Rheum Dis. 2017;76:1906&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">28733473</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2017-211284</ArticleId></ArticleIdList></Reference><Reference><Citation>Lubrano E, Scriffignano S, Perrotta FM. Clinical characteristics of &#x201c;severe&#x201d; peripheral psoriatic arthritis: a retrospective analysis of a longitudinal cohort. Rheumatol Ther. 2024;11:663&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">38592646</ArticleId><ArticleId IdType="pmc">11111618</ArticleId><ArticleId IdType="doi">10.1007/s40744-024-00667-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Queiro R, Seoane-Mato D, Laiz A, et al. Severe disease in patients with recent-onset psoriatic arthritis. Prediction model based on machine learning. Front Med (Lausanne). 2022;9:891863.</Citation><ArticleIdList><ArticleId IdType="pubmed">35572968</ArticleId><ArticleId IdType="doi">10.3389/fmed.2022.891863</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogdie A, Coates LC, Mease P. Measuring outcomes in psoriatic arthritis. Arthritis Care Res (Hoboken). 2020;72:82&#x2013;109.</Citation><ArticleIdList><ArticleId IdType="pubmed">33091263</ArticleId><ArticleId IdType="pmc">8528225</ArticleId><ArticleId IdType="doi">10.1002/acr.24242</ArticleId></ArticleIdList></Reference><Reference><Citation>Eder L, Thavaneswaran A, Chandran V, et al. Factors explaining the discrepancy between physician and patient global assessment of joint and skin disease activity in psoriatic arthritis patients. Arthritis Care Res (Hoboken). 2015;67:264&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">25047020</ArticleId><ArticleId IdType="doi">10.1002/acr.22401</ArticleId></ArticleIdList></Reference><Reference><Citation>Lebwohl MG, Kavanaugh A, Armstrong AW, et al. US perspectives in the management of psoriasis and psoriatic arthritis: patient and physician results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey. Am J Clin Dermatol. 2016;17:87&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">26718712</ArticleId><ArticleId IdType="doi">10.1007/s40257-015-0169-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacrist&#xe1;n JA, Dilla T, D&#xed;az-Cerezo S, et al. Patient-physician discrepancy in the perception of immune-mediated inflammatory diseases: rheumatoid arthritis, psoriatic arthritis and psoriasis. A qualitative systematic review of the literature. PLoS One. 2020;15:e0234705.</Citation><ArticleIdList><ArticleId IdType="pubmed">32555708</ArticleId><ArticleId IdType="pmc">7299355</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0234705</ArticleId></ArticleIdList></Reference><Reference><Citation>Mease PJ, Karki C, Palmer JB, et al. Clinical and patient-reported outcomes in patients with psoriatic arthritis (PsA) by body surface area affected by psoriasis: results from the Corrona PsA/Spondyloarthritis Registry. J Rheumatol. 2017;44:1151&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">28620063</ArticleId><ArticleId IdType="doi">10.3899/jrheum.160963</ArticleId></ArticleIdList></Reference><Reference><Citation>Mease PJ, Karki C, Palmer JB, et al. Clinical characteristics, disease activity, and patient-reported outcomes in psoriatic arthritis patients with dactylitis or enthesitis: results from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. Arthritis Care Res (Hoboken). 2017;69:1692&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">28376239</ArticleId><ArticleId IdType="doi">10.1002/acr.23249</ArticleId></ArticleIdList></Reference><Reference><Citation>Mease PJ, Liu M, Rebello S, et al. Association of nail psoriasis with disease activity measures and impact in psoriatic arthritis: data from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. J Rheumatol. 2021;48:520&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">33060307</ArticleId><ArticleId IdType="doi">10.3899/jrheum.190923</ArticleId></ArticleIdList></Reference><Reference><Citation>Mease PJ, Palmer JB, Liu M, et al. Influence of axial involvement on clinical characteristics of psoriatic arthritis: analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. J Rheumatol. 2018;45:1389&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">29961691</ArticleId><ArticleId IdType="doi">10.3899/jrheum.171094</ArticleId></ArticleIdList></Reference><Reference><Citation>Tillett W, Merola JF, Thaci D, et al. Disease characteristics and the burden of joint and skin involvement amongst people with psoriatic arthritis: a population survey. Rheumatol Ther. 2020;7:617&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">32700230</ArticleId><ArticleId IdType="pmc">7410983</ArticleId><ArticleId IdType="doi">10.1007/s40744-020-00221-8</ArticleId></ArticleIdList></Reference><Reference><Citation>McInnes IB, Rahman P, Gottlieb AB, et al. Efficacy and safety of guselkumab, an interleukin-23p19-specific monoclonal antibody, through one year in biologic-naive patients with psoriatic arthritis. Arthritis Rheumatol. 2021;73:604&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">33043600</ArticleId><ArticleId IdType="pmc">9291746</ArticleId><ArticleId IdType="doi">10.1002/art.41553</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchlin CT, Helliwell PS, Boehncke WH, et al. Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-na&#xef;ve or TNF&#x3b1; inhibitor-experienced. RMD Open. 2021;7:e001457.</Citation><ArticleIdList><ArticleId IdType="pubmed">33568556</ArticleId><ArticleId IdType="pmc">7880108</ArticleId><ArticleId IdType="doi">10.1136/rmdopen-2020-001457</ArticleId></ArticleIdList></Reference><Reference><Citation>McInnes IB, Rahman P, Gottlieb AB, et al. Long-term efficacy and safety of guselkumab, a monoclonal antibody specific to the p19 subunit of interleukin-23, through two years: Results from a phase III, randomized, double-blind, placebo-controlled study conducted in biologic-naive patients with active psoriatic arthritis. Arthritis Rheumatol. 2022;74:475&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">34719872</ArticleId><ArticleId IdType="pmc">9305108</ArticleId><ArticleId IdType="doi">10.1002/art.42010</ArticleId></ArticleIdList></Reference><Reference><Citation>Coates LC, Gossec L, Zimmerman M, et al. Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo controlled study. RMD Open. 2024;10:e003977.</Citation><ArticleIdList><ArticleId IdType="pubmed">38531621</ArticleId><ArticleId IdType="pmc">10966800</ArticleId><ArticleId IdType="doi">10.1136/rmdopen-2023-003977</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchlin CT, Mease PJ, Boehncke WH, et al. Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study. Clin Rheumatol. 2024;43:2551&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">38844682</ArticleId><ArticleId IdType="pmc">11269379</ArticleId><ArticleId IdType="doi">10.1007/s10067-024-06991-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-na&#xef;ve patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395:1126&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">32178766</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(20)30263-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoels M, Aletaha D, Funovits J, et al. Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis. 2010;69:1441&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">20525844</ArticleId><ArticleId IdType="doi">10.1136/ard.2009.122259</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandran V, Bhella S, Schentag C, et al. Functional assessment of chronic illness therapy-fatigue scale is valid in patients with psoriatic arthritis. Ann Rheum Dis. 2007;66:936&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17324972</ArticleId><ArticleId IdType="pmc">1955111</ArticleId><ArticleId IdType="doi">10.1136/ard.2006.065763</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoels MM, Aletaha D, Alasti F, et al. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis. 2016;75:811&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">26269398</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2015-207507</ArticleId></ArticleIdList></Reference><Reference><Citation>Helliwell PS, FitzGerald O, Fransen J, et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis. 2013;72:986&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">22798567</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2012-201341</ArticleId></ArticleIdList></Reference><Reference><Citation>Helliwell PS, Deodhar A, Gottlieb AB, et al. Composite measures of disease activity in psoriatic arthritis: comparative instrument performance based on the efficacy of guselkumab in an interventional phase II trial. Arthritis Care Res (Hoboken). 2020;72:1579&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">31421033</ArticleId><ArticleId IdType="pmc">7702129</ArticleId><ArticleId IdType="doi">10.1002/acr.24046</ArticleId></ArticleIdList></Reference><Reference><Citation>Cauli A, Gladman DD, Mathieu A, et al. Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study. J Rheumatol. 2011;38:898&#x2013;903.</Citation><ArticleIdList><ArticleId IdType="pubmed">21324965</ArticleId><ArticleId IdType="doi">10.3899/jrheum.100857</ArticleId></ArticleIdList></Reference><Reference><Citation>Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis. 2010;69:48&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">19147615</ArticleId><ArticleId IdType="doi">10.1136/ard.2008.102053</ArticleId></ArticleIdList></Reference><Reference><Citation>Lubrano E, Perrotta FM, Parsons WJ, et al. Patient&#x2019;s global assessment as an outcome measure for psoriatic arthritis in clinical practice: a surrogate for measuring low disease activity? J Rheumatol. 2015;42:2332&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">26523033</ArticleId><ArticleId IdType="doi">10.3899/jrheum.150595</ArticleId></ArticleIdList></Reference><Reference><Citation>Haroon M, Gallagher P, FitzGerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis. 2015;74:1045&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">24525911</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2013-204858</ArticleId></ArticleIdList></Reference><Reference><Citation>Snoeck Henkemans SVJ, de Jong PHP, Luime JJ, et al. Window of opportunity in psoriatic arthritis: the earlier the better? RMD Open. 2024;10:e004062.</Citation><ArticleIdList><ArticleId IdType="pubmed">38413172</ArticleId><ArticleId IdType="pmc">10900390</ArticleId><ArticleId IdType="doi">10.1136/rmdopen-2023-004062</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottlieb AB, McInnes IB, Rahman P, et al. Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naive patients with active psoriatic arthritis. RMD Open. 2023;9:e002789.</Citation><ArticleIdList><ArticleId IdType="pubmed">36828643</ArticleId><ArticleId IdType="pmc">9972414</ArticleId><ArticleId IdType="doi">10.1136/rmdopen-2022-002789</ArticleId></ArticleIdList></Reference><Reference><Citation>Talli S, Etcheto A, Fautrel B, et al. Patient global assessment in psoriatic arthritis&#x2014;What does it mean? An analysis of 223 patients from the psoriatic arthritis impact of disease (PsAID) study. Joint Bone Spine. 2016;83:335&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">26677994</ArticleId><ArticleId IdType="doi">10.1016/j.jbspin.2015.06.018</ArticleId></ArticleIdList></Reference><Reference><Citation>Lubrano E, Scriffignano S, Azuaga AB, et al. Impact of comorbidities on disease activity, patient global assessment, and function in psoriatic arthritis: a cross-sectional study. Rheumatol Ther. 2020;7:825&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">32804332</ArticleId><ArticleId IdType="pmc">7695787</ArticleId><ArticleId IdType="doi">10.1007/s40744-020-00229-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Mease PJ, Gladman DD, Poddubnyy D, et al. Efficacy of guselkumab on axial-related symptoms through up to 2 years in adults with active psoriatic arthritis in the phase 3, randomized, placebo-controlled DISCOVER-2 study. Rheumatol Ther. 2023;10:1637&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">37819505</ArticleId><ArticleId IdType="pmc">10654317</ArticleId><ArticleId IdType="doi">10.1007/s40744-023-00592-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Mease PJ, Helliwell PS, Gladman DD, et al. Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies. Lancet Rheumatol. 2021;3:e715&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">38287608</ArticleId><ArticleId IdType="doi">10.1016/S2665-9913(21)00105-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman DD, Mease PJ, Bird P, et al. Efficacy and safety of guselkumab in biologic-naive patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial. Trials. 2022;23:743.</Citation><ArticleIdList><ArticleId IdType="pubmed">36064592</ArticleId><ArticleId IdType="pmc">9444112</ArticleId><ArticleId IdType="doi">10.1186/s13063-022-06589-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogdie A, Husni ME, Scher J, et al. SAT0434 Minimal clinically important difference in outcome measures for use in clinical care and pragmatic trials in PsA. Ann Rheum Dis. 2020;79(Suppl 1):1173&#x2013;4.</Citation></Reference><Reference><Citation>Helliwell PS, FitzGerald O, Fransen J. Composite disease activity and responder indices for psoriatic arthritis: a report from the GRAPPA 2013 meeting on development of cutoffs for both disease activity states and response. J Rheumatol. 2014;41:1212&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">24882854</ArticleId><ArticleId IdType="doi">10.3899/jrheum.140172</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulder MLM, Bertram AM, Wenink MH, et al. Defining the minimal important change (MIC) and meaningful change value (MCV) for the Psoriatic Arthritis Disease Activity Score (PASDAS) in a routine practice cohort of patients with psoriatic arthritis. Rheumatology (Oxford). 2022;61:4119&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">35025996</ArticleId><ArticleId IdType="doi">10.1093/rheumatology/keac025</ArticleId></ArticleIdList></Reference><Reference><Citation>Tillett W, Day J, McHugh NJ, et al. OP0224 Continuous composite measures for routine care in psoriatic arthritis: thresholds of meaning and clinically important difference estimates for the 3 and 4 VAS scales from a UK multicentre study. Ann Rheum Dis. 2021;80 (Suppl 1):135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-eular.1622</ArticleId></ArticleIdList></Reference><Reference><Citation>Institute for Quality and Efficiency in Health Care. General Methods Version 6.1. Jan 2022. https://www.iqwig.de/methoden/general-methods_version-6-1.pdf .</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>